GlassScriptPhysician profile
Raouf E Hilal
NPI 1427161793
$13,098.63
in general payments reported to CMS, 2019-2025
43 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $985 · 2021: $1,433 · 2022: $1,753 · 2023: $2,453 · 2024: $2,488 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,113 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,112.98 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,116.69 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,458.51 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $849.20 | 2021-2024 | Zeposia |
| Pfizer INC. | $826.80 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $756.79 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $543.97 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $435.76 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $420.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $396.37 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $370.33 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $365.11 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $292.92 | 2019-2025 | Ocaliva |
| Vivus LLC | $188.53 | 2019-2024 | Qsymia |
| Allergan, INC. | $185.33 | 2019-2020 | |
| Genzyme Corporation | $162.72 | 2022-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $160.14 | 2020-2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $158.52 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $158.17 | 2022-2025 | Ibsrela |
| Amgen INC. | $136.36 | 2022-2025 | Amjevita, Avsola, Uplizna |
| Ferring Pharmaceuticals INC. | $106.32 | 2022-2024 | Rebyota |
| Qol Medical, LLC | $102.00 | 2020-2023 | Sucraid |
| Lilly USA, LLC | $95.39 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $93.83 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $69.01 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $65.74 | 2023 | Idacio |
| Romark Laboratories, Lc | $64.54 | 2019-2020 | |
| Novo Nordisk INC | $59.90 | 2025 | Wegovy |
| Celltrion USA INC. | $58.56 | 2024-2025 | Zymfentra, Vegzelma |
| Enterra Medical, INC. | $53.45 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $49.66 | 2022-2024 | Givlaari |
| Ucb, INC. | $41.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.36 | 2023 | Cyltezo |
| Boston Scientific Corporation | $41.27 | 2023 | Compliance Endokit |
| Merck Sharp & Dohme LLC | $38.02 | 2023-2024 | Dificid, Recarbrio |
| Exact Sciences Corporation | $17.91 | 2023 | Cologuard Collection Kit |
| Alfasigma USA, INC. | $17.16 | 2020 | |
| Braintree Laboratories, INC. | $16.77 | 2024 | Suflave |
| Medtronic, INC. | $15.79 | 2021 | |
| Shire North American Group INC | $14.53 | 2019 | |
| Ethicon US, LLC | $14.00 | 2019 | |
| Covidien LP | $13.83 | 2019 | |
| Daiichi Sankyo INC. | $13.40 | 2022 | |
| Endo Pharmaceuticals INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raouf Hilal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.